Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Bill.com Holdings Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Bill.com Holdings Inc trades at $41.2 (market cap $4.12B). The key difference: Bill.com Holdings Inc is far larger — about 5× Amphastar Pharmaceuticals Inc's market cap, and Bill.com Holdings Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | BILL | |
|---|---|---|
Market Cap | $826.08M | $4.12B |
Sector | Health | Technology |
52-Week High | $30.81 | $56.32 |
52-Week Low | $16.87 | $31.96 |
Enterprise Value | $1.22B | $3.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
BILL Holdings trades at $41.36, up 2.07% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical outlook with support at $39 and resistance at $42. Revenue growth accelerated to $1.46 billion in 2025, though net margins remain thin at 0.01%. Recent leadership changes and a $1 billion buyback program signal confidence in future growth.
Outlook remains positive with 56% analyst buy ratings and a $48 consensus target suggesting 16% upside. Key risks include high valuation (P/E 214), competitive pressures in SMB software, and sensitivity to interest rate changes. The company's transition to profitability and AI integration present opportunities if execution continues improving.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
